Teva received an appellate court ruling suggesting that CMS did not have authority from Congress to define a bona fide marketing standard for its IRA Medicare Fair Price negotiations. How does this relate to products targeted for IPAY negotiations and biosimilar competitors? This week, Teva received an appellate court ruling on the IRA Medicare Fair … Continue reading The Bona Fide Marketing Standard and What That Means for Biosimilars and Generics